Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Nelson, Noele P.
• Corporate Authors:
  National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U.S.)Division of Viral Hepatitis.
• Description:
  GamaSTAN S/D (Grifols Therapeutics, Inc., Research Triangle Park, North Carolina) is a sterile, preservative-free solution of immune globulin (IG) for intramuscular administration and is used for prophylaxis against disease caused by infection with hepatitis A, measles, varicella, and rubella Viruses (1). GamaSTAN S/D is the only IG product approved by the Food and Drug Administration for hepatitis A Virus (HAV) prophylaxis. In July 2017, GamaSTAN S/D prescribing information was updated with changes to the dosing instructions for hepatitis A preexposure and postexposure prophylaxis indications. These changes were made because of concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma (2). No changes in dosing instructions were made for measles, varicella, or rubella preexposure or postexposure prophylaxis.
• Subjects:
  Full Report Hepatitis A Humans Immunoglobulin G Post-Exposure Prophylaxis Practice Guidelines As Topic Pre-Exposure Prophylaxis
• Source:
  MMWR Morbidity Mortal Weekly Rep. 66(36):959-960.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6636a5
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  28910270
• Pubmed Central ID:
  PMC5657912
• Document Type:
  Journal Article
• Pages in Document:
  2 pdf pages
• Volume:
  66
• Issue:
  36
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:b0c61fff521b361941ea30713eb30c8062bf01079aa79d2e559a42f29d7f2e872d7e83f8302fd701eb23d4a0bf9b451427bb2c14cf538537781ef13bf8568198
• Download URL:
  https://stacks.cdc.gov/view/cdc/54628/cdc_54628_DS1.pdf
• File Type:
  [PDF - 117.55 KB ]